In October, of the seven analysts covering Viking Therapeutics (VKTX), one has given its stock a “strong buy” rating, and six have given it “buy” ratings.
The mean rating for Viking stock is 1.86, and its target price is $32.33, implying an upside potential of 112.1% over its closing price of $15.24 on October 2.
Viking Therapeutics has been on investors’ radar in 2018 and has generated strong returns so far. From $4.38 on January 17, the stock rose to $10.23 on June 12. After trading at this level for the next two months, it continued its climb and reached $22.16 on September 19, which was a high point for it in 2018. Viking stock has sharply corrected to its current level of $15 this month.
Viking’s EV (enterprise value) is $953.92 million, and its price-to-book ratio is 6.59.
Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 35.10. In comparison, the current ratios of BeyondSpring and Ra Pharmaceuticals stand at 4 and 11.60, respectively, indicating that Viking Therapeutics is in a better position to satisfy its short-term obligations than its peers.
Viking Therapeutics’ cash per share stands at $2.25, while BeyondSpring and Ra Pharmaceuticals have cash per share of $0.96 and $3.09, respectively.